Biogen (($CC:HTER)) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) has announced an update on its ...

Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of kidney transplant loss, with ...

Felzartamab is an investigational, fully human IgG1 monoclonal anti-CD38 antibody that has a high potential to deplete CD38-positive plasma cells that produce and secrete these destructive ...

(RTTNews) - Biogen Inc. (BIIB) announced that results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in individuals with IgA nephropathy or ...

Biogen (BIIB) presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in people living with IgA nephropathy. The results ...

Felzartamab for MM third-line treatment is on track for BLA submission in Q4 2021 New IND application for combination of felzartamab with another I-Mab clinical asset as a potential first-line ...